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The diagnostic methods currently used to distinguish between 
benign and malignant breast lesions are all invasive and 
often inconclusive. This may lead to surgery for histological 
assessment.1 The main objective of this study was to determine 
the diagnostic accuracy of SonoVue (Bracco spa, Milan) 
contrast-enhanced ultrasound as a diagnostic method, with 
histological examination as the reference standard.
Until recently SonoVue was mainly used for the assessment of 
liver conditions, with very few studies done on breast tissue.2,3 
A secondary aim of this study was to analyse the difference 
in the haemodynamics between both benign and malignant 
focal lesions compared with normal breast parenchyma. The 
haemodynamic assessment represented the global average blood 
flow over all the vessels, neovascular and normal capillaries 
within a selected region of interest (ROI). This will aid the 
vascular characterisation of various breast abnormalities, which 
will be of use when microbubbles are used as a treatment 
modality.4 
Methods
Selection and description of participants
In this prospective study, 50 consecutive patients (women 
aged 20 - 93 years, mean 55 years) with a breast lump were 
referred for clinical evaluation to the Breast Clinic of the 
Glasgow Royal Infirmary and Western Infirmary, UK, between 
July and December 2003. The lesions were diagnosed on 
combined clinical examination, sonography/mammography 
and histological examination. The histology result served as 
the reference standard. All the patients were aware of their 
confirmed diagnosis at the time of the contrast-enhanced 
ultrasound. 
Inclusion criteria were unilateral abnormal breast lumps 
and a normal contralateral breast, informed consent from the 
patient, and ability to locate the lump by ultrasound and to 
identify its central area.
Exclusion criteria were bilateral breast disease, or 
abnormal contralateral breast tissue; any contraindication 
to the imaging investigations and/or histology/pathology 
examination; participation in another clinical study involving 
an investigational drug in the last 30 days; any medical condition 
or circumstances that would have significantly decreased the 
chances of obtaining reliable data or of achieving the study 
objectives, such as dementia, or other reasons for expected poor 




SonoVue was supplied as a sterile, lyophilised powder 
contained in a septum-sealed vial. A white milky suspension 
of sulphur hexafluoride (SF6) microbubbles was obtained by 
adding 5 ml physiological saline (0.9% sodium chloride) to the 
powder (25 mg), using standard aseptic techniques, followed 
by hand agitation.
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Objective. To determine the diagnostic value of haemodynamic 
contrast-enhanced ultrasound assessment in benign and 
malignant breast tissue, using histological examination as the 
reference standard.
Methods. An HDI 5000 Phillips ultrasound scanner with 
microvascular imaging software and 2.5 ml SonoVue (Bracco 
spa, Milan) contrast was used to scan 50 consecutive patients 
(32 malignant and 18 benign, 49 with histologically confirmed 
breast lesions). Time-intensity curves of the regions of interest 
(ROI) placed over the lesional and normal breast tissues were 
acquired using QLAB software. The area under the curve 
(AUC), time to peak (TTP), in-flow gradient (IFG) and peak 
enhancement (PE) were determined in a standardised manner 
for each focal breast lesion and the control/normal breast. 
IFG and AUC in the periphery, and PE and AUC in the centre 
of the lesions, differed significantly between malignant and 
benign tumours. In a logistical regression model, AUC in the 
periphery and the ratio of PE at the tumour centre to that of 
normal breast were independently predictive of malignancy 
(p<0.001), achieving a diagnostic sensitivity of 97% and a 
specificity of 80% in the 41 tumours in which central vessels 
could be distinguished.
Conclusion. Haemodynamic contrast-enhanced ultrasound 
assessment can be used to distinguish between benign and 
malignant breast lesions.
S Afr Med J 2008; 98: 386-391.
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Each patient received 2 intravenous bolus injections of 
SonoVue (2 boluses of 2.5 ml) via a 20-gauge intravenous 
catheter placed in the antecubital vein for each lesion to be 
characterised, followed by 3 ml of saline flush. 
Study design
Screening (physical examination, pregnancy test whenever 
applicable, medical history and concomitant medication), the 
triple assessment and informed written consent were obtained 
before the contrast-enhanced ultrasound investigation. All 
patients were monitored for adverse events until 2 hours after 
the administration of SonoVue. 
Ultrasound investigations
A Phillips HDI 5000 ultrasound scanner equipped with non-
linear imaging capabilities was used in the Department of 
Surgery at the Glasgow Royal Infirmary. Technical settings 
such as mechanical index (MI) and frame rate were optimised 
to obtain images of the best quality (MI 0.06, frame rate 
13/second). Contrast-enhanced ultrasound was performed 
in a standardised manner in a single plane after an IV bolus 
injection of 2.5 ml SonoVue and 3 ml saline flush.
To establish the location of the lesion, all patients had 
an unenhanced ultrasound scan using fundamental mode, 
followed by contrast-enhanced ultrasonography in greyscale, 
with non-linear imaging modes using continuous real-time 
imaging. The first enhanced study was over the lump and 
the second over a similar area of the contralateral breast. The 
normal breast served as the control. The enhanced sonographic 
examinations were recorded on CD-ROM. 
QLAB (Phillips) ultrasound image analysing software 
transmitted the image to a computer screen. A ROI of 5 mm² 
was selected over the periphery and over the centre of the focal 
lesion, using the accumulation image.
A time signal intensity curve was derived for both these 
areas. The data of these curves were automatically transferred 
to a Microsoft Excel file, which was used to determine the time 
to peak (TTP), area under the curve (AUC), in-flow gradient 
(IFG) and peak enhancement (PE) in a standard manner. 
Finally, the results were compared with the initial histological 
diagnosis.
Reference standard 
Histological results were based on fine-needle aspirates, core 
biopsies and excised tumours. Ninety-eight per cent of the 
patients had a pathology result. One patient had a clinically 
evident carcinoma, without histological confirmation. This was 
added to ‘Carcinoma not otherwise specified’ (see Table II).
The final diagnosis was based on the findings of combined 
clinical examination, mammography/sonography and 
histology/pathology. Biopsies and aspirates were performed 
more than 2 weeks before the ultrasound study.
Definitions 
Definitions are as follows: Region of interest (ROI): 5 mm 
square – QLAB software; Peripheral: on the edge between the 
normal and abnormal tissue, selected on the lesion; Central: 
centre of the lesion (could not be determined in scattered/small 
lesions); Control breast: contralateral breast without clinical 
or imaging evidence of breast disease; time to peak (TTP) = 
(time at peak) – (time at inflow), SI unit: seconds; area under 
the curve (AUC) = (echo2 + echo1)*(time2 – time1)/2; in-flow 
gradient (IFG): graph-fit-straight-line over contrast in-flow; 
peak-enhancement (PE) = (peak echo) – (background echo).
Statistics 
Comparison between the abnormal and normal breast of each 
patient was performed using Wilcoxon’s signed-rank test. 
Comparisons between malignant and benign breast lumps 
were performed using the Mann-Whitney test. The ability 
of the ultrasound-derived variables to distinguish between 
malignant and benign lumps was assessed using logistical 




A total of 50 women aged 20 - 93 years (mean age 55 years) 
with a breast lump were referred for clinical evaluation to the 
Breast Clinic of the Glasgow Royal Infirmary and Western 
Infirmary, UK, between July and December 2003.
All the patients were examined clinically. Seventy-four per 
cent had a mammogram, 32% had an unenhanced ultrasound 
scan, 64% had a fine-needle aspirate, 86% had a core biopsy 
and 98% had a pathology result.
One malignant and 8 benign tumours were excluded because 
the central area could not be defined. 
Reference standard 
Histological examination revealed the presence of 32 breast 
cancers and 18 benign lesions (fibro-adenoma, fibrocystic 
changes, fat necrosis and fibrosis). The histopathological 
classification of the malignant and benign lesions is given in 
Tables I and II.
The mean diameter of all combined lumps was 2.5 cm (range 
0.5 - 5 cm). The mean diameter of malignant lesions was 2.9 cm 
(0.5 - 5 cm), and of benign lesions 1.5 cm (1 - 2 cm).
Twenty-nine of the patients with malignant disease 
underwent breast surgery and the abnormal lesions were 
surgically removed. The remaining patients had a histological 
diagnosis made on core biopsy alone. Two patients were 
treated with neo-adjuvant chemotherapy before surgery and 
3 patients received only hormonal treatment for their breast 
cancer. All the patients had unilateral breast disease. Of the 
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32 invasive lesions, all were primary cancers, there were no 
recurrences or metastatic tumours, and 1 was a Mercel cell 
carcinoma. 
Test results and estimation 
Comparison of tumour and normal tissue 
The haemodynamic results for the measurements taken over 
the peripheral infiltrating vessels are given in Table III. 
In malignant tumours, the TTP was significantly reduced 
and the in-flow gradient and AUC were significantly increased 
relative to the contralateral normal breast (all p<0.001). Peak 
enhancement was non-significantly increased in tumour tissue 
(p=0.08).
In the peripheral vessels of benign lesions, the TTP was 
significantly reduced (p<0.001) and the in-flow gradient 
significantly increased (p=0.049), but there was no significant 
overall difference between tumour and normal tissue in AUC 
(p=0.16) or peak enhancement (p=0.87). 
Ultrasound measurements were performed over the central 
area of the tumour in 31 malignant and 10 benign tumours 
(Table IV). The other 1 malignant and 8 benign tumours were 
excluded because the central area could not be defined. 
In contrast to the results in peripheral vessels, in central 
vessels of malignant tumours the TTP, in-flow gradient, AUC 
and peak enhancement were all significantly reduced (p<0.001, 
p=0.014, p<0.001 and p<0.001 respectively) relative to the 
contralateral normal breast. 
In benign tumours, the TTP in central vessels was reduced 
(p=0.008), but there was no significant change in the other 
variables relative to normal breast.
Comparison of malignant and benign tumours 
The in-flow gradient in peripheral vessels was significantly 
greater in malignant than benign tumours both in absolute 
terms (p=0.01) and relative to the gradient in normal breast 
(p=0.02). Similarly, the AUC in peripheral vessels was higher in 
malignant than benign tumours in both absolute and relative 
terms (p=0.001). 
By contrast, in central vessels, the in-flow gradient tumour-
to-normal ratio, the AUC (absolute and ratio), and the peak 
enhancement (absolute and ratio) were all significantly lower 
in malignant than benign tumours (p<0.05). 
The variables that differed significantly between benign 
and malignant tumours were assessed in a multiple logistical 
Table I. Benign tumours (N=18) 
     Total number
Fibro-adenoma              6
Fibrocystic               9
Fat necrosis              2
Fibrosis               1
   Total             18
Table II. Malignant tumours (N=31) 
     Total number
Intraductal carcinoma           25
Intralobular carcinoma             1
Mixed               2
Mercel cell carcinoma             1
Carcinoma not otherwise specified             2
   Total             31
Table III. Ultrasound measurements in tumour peripheral vessels and normal breast tissue in patients with malignant and 
benign breast lumps (results expressed as median and interquartile range) 
Variable (peripheral vessels)  Malignant tumours (N=32)  Benign tumours (N=18)  p-value
TTP 
Tumour   36.1 (32.5 - 36.9)*   36.8 (36.3 - 37.1)*   0.069
Normal breast   36.9 (35.9 - 37.6)   37.2 (36.9 - 37.5)   0.32
T/N ratio   0.98 (0.97 - 0.99)   0.99 (0.98 - 1.00)   0.39
In-flow gradient 
Tumour   0.78 (0.67 - 1.56)*   0.60 (0.27 - 0.80)†   0.011
Normal breast   0.41 (0.19 - 0.67)   0.36 (0.20 - 0.62)   0.85
T/N ratio    2.35 (1.59 - 3.71)   1.29 (0.95 - 2.78)   0.021
AUC 
Tumour   298 (225 - 380)*   171 (126 - 271)   0.001
Normal breast   207 (150 - 314)   199 (157 - 294)   0.79
T/N ratio   1.24 (1.00 - 1.64)   0.893 (0.68 - 1.05)   0.001
Peak enhancement 
Tumour   8.1 (5.8 - 10.9)   6.3 (3.9 - 9.4)   0.08
Normal breast   7.4 (4.9 - 9.2)   5.8 (4.4 - 7.4)   0.25
T/N ratio    1.08 (0.90 - 1.47)   0.99 (0.70 - 1.34)   0.42
*p<0.001 for comparison of tumour with normal breast in the same patient. 
†p<0.05.
TTP = time to peak; T/N ratio = tumour/normal ratio; AUC = area under the curve.
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regression analysis with forward stepwise selection, to 
construct a model combining independently significant 
predictive variables. When the analysis was restricted to 
measurements in peripheral vessels, so as to include all 
tumours, only the AUC had significant independent predictive 
power (p<0.001). When the analysis included measurements 
in both peripheral and central vessels, hence excluding 
those tumours in which central measurements were not 
available, both the AUC in peripheral vessels (p<0.001) and 
the tumour-to-normal ratio of peak enhancement in central 
vessels (p<0.001) were independently significant. The logistical 
regression equation relating the log of the odds of a tumour 
being malignant to the ultrasound variables was as follows: 
log odds = 6.56 PEtc/PEcon – 0.028 AUCtp – 0.51, where AUCtp 
= area under curve, tumour peripheral vessels, PEtc = peak 
enhancement, tumour central vessels, and PEcon = peak 
enhancement, normal breast. 
Fig. 1 shows the receiver operator characteristic (ROC) 
curves associated with AUCtp alone and AUCtp in combination 
with PEtc/PEcon. Table V shows the sensitivity and specificity 
achieved for each of these predictive models at thresholds that 
maximised the number of tumours correctly classified in this 
cohort. Measurements in peripheral vessels alone had poor 
specificity in identifying malignant tumours, and addition of 
the measurements in central vessels greatly improved accuracy 
in the subset of tumours in which these measurements were 
available.
Discussion 
SonoVue is currently the most widely available ultrasound 
contrast agent in Europe for radiology applications and 
has replaced Levovist as the latter is no longer available or 
manufactured for Europe.5 The advent of the improved non-
linear imaging modes combined with low mechanical index 
imaging has been a significant advance for the use of SonoVue 
clinically, as it enables continued real-time imaging with 
minimal microbubble destruction.4 
The real-time demonstration of the contrast enhancement of 
the lesion relative to the control breast is the key to improving 
lesion characterisation, as shown in this study.
Table IV. Ultrasound measurements in tumour central vessels and normal breast tissue in patients with malignant and benign 
breast lumps (results expressed as median and interquartile range)
Variable 
(central vessels)  Malignant tumours (N=31)  Benign tumours (N=10)  p-value
TTP 
Tumour  36.1 (35.3 - 36.5)*   36.4 (36.2 - 36.7)†   0.18
Normal breast  36.9 (36.1 - 37.6)   37.2 (37.0 - 37.6)   0.33
T/N ratio  0.97 (0.96 - 0.99)   0.98 (0.96 - 0.99)   0.95
In gradient 
Tumour  0.20 (0.20 - 0.30)‡   0.40 (0.20 - 1.43)   0.21
Normal breast  0.41 (0.19 - 0.69)   0.30 (0.13 - 0.49)   0.24
T/N ratio  0.58 (0.42 - 1.25)   1.50 (0.86 - 5.00)   0.034
AUC 
Tumour  104 (82 - 133)*   182 (116 - 323)   0.011
Normal breast  208 (160 - 315)   196 (121 - 244)   0.48
T/N ratio   0.44 (0.33 - 0.75)   1.10 (0.65 - 2.01)   0.008
Peak enhancement 
Tumour  3.0 (2.3 - 4.0)*   7.3 (4.5 - 9.2)   0.002
Normal breast  7.6 (4.9 - 9.2)   4.8 (3.7 - 6.4)   0.11
T/N ratio  0.45 (0.36 - 0.66)   1.27 (0.82 - 2.07)   < 0.001
*p<0.001 for comparison of tumour with normal breast in the same patient.
†p<0.01. 
‡p<0.05. 
TTP = time to peak; T/N ratio = tumour/normal ratio; AUC = area under the curve. 
Fig. 1. ROC curves for distinguishing malignant and benign 
tumours using ultrasound measurements in peripheral vessels 
only or in both peripheral and central vessels. The test variables are 
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The contralateral breast was used as the control in this 
study; it has been proved that malignancy in a breast causes a 
generalised increase in flow over the entire affected breast.6 All 
the patients in this study had unilateral breast disease, without 
known metastases and there was no significant difference 
in the blood flow between the various groups of patients 
concerning the control breast. Previous studies on blood flow 
assessment in focal lesions have led to inconsistent results and 
it may well have been because the lesions were compared with 
the surrounding tissue, where the flow was increased because 
of the malignant lesion. 
Two specific areas in the tumour were haemodynamically 
assessed, as previous studies7 have indicated that an increased 
vessel count and flow could be demonstrated over the 
periphery of the cancer and that the centre of the cancer was 
associated with a decrease in number of vessels and flow. This 
study demonstrated that this was true when both malignant 
and benign lumps were compared with the control breast.
Quantitative analyses on a ROI including the entire tumour 
volume led to inconsistent results, possibly because of the ill-
defined margins in some tumours. 
The majority of benign lumps assessed in this study 
were fibrocystic changes, which occur because of hormonal 
influences in the breast. The increased flow to these cysts may 
be a result of inflammation associated with this condition. 
Similarly, there was an increased flow but decreased AUC in 
fat necrosis.
The flow pattern of fibro-adenomas was exactly the opposite 
of the malignant tumours. Where malignant tumours had an 
increased flow and AUC over the periphery of the lump, the 
fibro-adenomas demonstrated an increased flow and AUC 
over the central aspect of the lump; this may indicate the 
mechanism of growth. The relative avascular state of fibrosis 
may explain the decrease in the AUC.
There were limitations in the design of the study. Analysis 
of the contrast-enhanced ultrasound scans was always done 
after triple assessment of the lesion and the diagnosis was 
available at the time of the assessment. The breast biopsies 
could have had an effect on the vascularity. We have not been 
able to demonstrate the effect. Ideally it should have been 
a blinded study and the analyses should have been done 
before breast biopsy, but the current set-up was meant to 
mirror clinical practice. In addition, the majority of malignant 
lumps were surgically removed for pathological examination 
and not all the benign lumps, which could potentially have 
led to misdiagnosis of a few benign lumps. However there 
is proof that once a benign lesion has been diagnosed by 
triple assessment, it can safely be left behind.8 Furthermore, 
enhancement was not always adequate to determine the central 
aspect of the lesion at 2.5 ml of SonoVue and pulse inversion; it 
may improve with 5 ml of contrast.
Nevertheless, in this study we have shown an improvement 
in the characterisation of focal breast lesions based on 
real-time assessment of the differential tumour SonoVue 
enhancement characteristics with regard to the normal breast. 
The results have shown that SonoVue-enhanced ultrasound 
significantly increased both the sensitivity and specificity in 
the characterisation of focal breast lesions. There was also a 
significant reduction in the number of indeterminate diagnoses 
following SonoVue-enhanced ultrasound.
Differentiation between the benign and malignant lesions 
may be difficult in some instances, e.g. fat necrosis with 
calcification or fibrosis post lumpectomy, more so when the 
lesion is small, when the characteristic features may lead 
to confusion and the biopsy can be difficult. In these cases 
contrast-enhanced ultrasound may be of benefit as it is non-
invasive and can provide real-time imaging.
No adverse effects were experienced by the patients in 
this study. SonoVue is considered to be a safe contrast for 
ultrasound of the breast.4,9 
Conclusion 
The results suggest that SonoVue-enhanced ultrasound with 
non-linear imaging modes improves the characterisation of 
focal breast lesions and could be implemented in clinical 
practice to limit unnecessary referral for further invasive and/
or costly imaging scans. However further studies are needed to 
confirm the results and reproducibility of this study.
Table V. Sensitivity, specificity and accuracy of ultrasound measurements in distinguishing malignant and benign tumours 
                 N (%) of tumours correctly classified
     Malignant   Benign   All tumours
Criterion     (sensitivity)  (specificity)  (accuracy)
Peripheral vessels only 
AUCt >175    29/32 (91)  10/18 (56)  39/50 (78)
Peripheral and central vessels 
6.56 PEtc/PEcon–0.028 AUCtp–0.51<0  30/31 (97)  8/10 (80)   38/41 (93)
AUCtp = area under the curve, tumour peripheral vessels; PEtc = peak enhancement, tumour central vessels; PEcon = peak enhancement, normal breast.
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Multiple sclerosis in South Africa
Girish Modi, Andre Mochan, Madelein du Toit, Ivan Stander
Three geographical zones based on worldwide prevalence 
are distinguishable for MS.1 High-incidence regions have a 
prevalence of >30 sufferers per 100 000 of the population, and 
include most of Europe, Israel, Canada, northern USA, south-
eastern Australia, New Zealand and eastern Russia. Medium-
frequency regions (5 - 30 per 100 000) include the southern 
USA, the rest of Australia, South Africa (SA), the southern 
Mediterranean basin, Russia (including Siberia), the Ukraine 
and parts of Latin America. Prevalence rates of <5 per 100 000 
include the rest of Asia, Africa and northern South America.1 
Regional categorisation of MS is based on extrapolations of 
known or documented prevalence and incidence statistics on 
MS from the USA, the UK, and parts of Europe.2 In the USA, 
the prevalence rate for MS is approximately 1 in 700 (0.14%). 
An extrapolated SA prevalence rate of 1 in 700 is described –  
63 497 MS sufferers. These figures, while inaccurate,2 also 
indicate a scarcity of literature on the prevalence and incidence 
of MS worldwide, including SA; we found only four such 
articles concerning SA.3-6 These discuss MS in the white 
population, differences in prevalence rates between immigrant 
and non-immigrant white populations, and the possibility of an 
increased MS prevalence in Afrikaans-speaking white people.6 
There are no reported nationwide epidemiological studies, and 
qualitative demographic data are also not available.
Design and methods
A patient-orientated questionnaire was distributed in a 
countrywide survey. It was made available on the website of 
the Multiple Sclerosis Society of South Africa (MSSA) (www.
multiplesclerosis.co.za), which has 1 760 members, and also 
distributed by email to 269 members and by post to 853 
members.
Results
Data from 430 patients, who responded over a period of 18 
months, were categorised as follows:
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Girish Modi, PhD, FCP (SA), FRCP
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Since there are no well-documented epidemiological studies 
on multiple sclerosis (MS) in South Africa, we devised a 
questionnaire to determine qualitative data. Responses were 
obtained from 430 patients: 91% had magnetic resonance 
imaging (MRI) scans, 64% had lumbar punctures and 49% 
had evoked potentials to establish the diagnosis of MS. A 
total of 71% of the respondents were aged 30 - 59 years, 73% 
were female, and 89% were white. In terms of MS type, 46% 
had relapsing-remitting MS, 13 % secondary progressive MS, 
12% primary progressive MS, 12% benign MS, and 17% not 
known. Disease-modifying treatment was not used by 32% 
of respondents, and 30% were treated with methotrexate and 
22% with interferon beta. These findings are similar to those 
in the literature, except for the under-utilisation of interferons 
as disease-modifying treatment.
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